313 related articles for article (PubMed ID: 24285921)
1. Canagliflozin: a novel treatment option for type 2 diabetes.
Dietrich E; Powell J; Taylor JR
Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter.
Toderika Y; Ferguson N
Cardiol Rev; 2014; 22(2):97-104. PubMed ID: 24500116
[TBL] [Abstract][Full Text] [Related]
4. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
[No Abstract] [Full Text] [Related]
5. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
9. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Matthaei S
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
[No Abstract] [Full Text] [Related]
10. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Boyle LD; Wilding JP
Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
[TBL] [Abstract][Full Text] [Related]
12. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Powell J; Miller SA; Taylor JR
South Med J; 2015 Feb; 108(2):82-90. PubMed ID: 25688892
[TBL] [Abstract][Full Text] [Related]
14. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Said S; Hernandez GT
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
Prescrire Int; 2015 Feb; 24(157):33-5. PubMed ID: 25802910
[TBL] [Abstract][Full Text] [Related]
17. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
Scheen AJ
Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
[TBL] [Abstract][Full Text] [Related]
18. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Bloomgarden Z
J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
[No Abstract] [Full Text] [Related]
19. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
20. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
Elmore LK; Baggett S; Kyle JA; Skelley JW
Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
